TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged
12 years and
older with severe asthma.
TEZSPIRE is not
indicated
for the relief of acute bronchospasm or status asthmaticus.
Enter your location below to find an alternate treatment site of care for the administration of the biologic TEZSPIRE.
No results. We are working to build network. Please try search different location
If you wish to add location, please submit here
AcariaHealth | |
Phone: | 1-800-511-5144 |
Fax: | 1-833-943-2432 |
Accredo Health Group | |
Phone: | 1-866-759-1557 |
Fax: | 1-888-302-1028 |
Walgreens Pharmacy | |
Phone: | 1-800-445-3674 |
Fax: | 1-866-773-0143 |
BioPlus | |
Phone: | 1-888-292-0744 |
Fax: | 1-800-269-5493 |
CVS Specialty | |
Phone: | 1-800-237-2767 |
Fax: | 1-800-323-2445 |
CenterWell Pharmacy | |
Phone: | 1-800-486-2668 |
Fax: | 1-877-405-7940 |
Kroger Specialty Pharmacy | |
Phone: | 1-855-733-3126 |
Fax: | 1-888-315-3270 |
Optum Specialty Pharmacy | |
Phone: | 1-855-427-4682 |
Fax: | 1-877-342-4596 |
Specialty Pharmacy | Phone | Fax |
---|---|---|
AcariaHealth | 1-800-511-5144 | 1-833-943-2432 |
Accredo Health Group | 1-866-759-1557 | 1-888-302-1028 |
Walgreens Pharmacy | 1-800-445-3674 | 1-866-733-0143 |
BioPlus | 1-888-292-0744 | 1-800-269-5493 |
CVS Specialty | 1-800-237-2767 | 1-800-323-2445 |
CenterWell Pharmacy | 1-800-486-2668 | 1-877-405-7940 |
Kroger Specialty Pharmacy | 1-855-733-3126 | 1-888-315-3270 |
Optum Specialty Pharmacy | 1-855-427-4682 | 1-877-342-4596 |
The Treatment Sites found within this website are provided for informational purposes only. The list is not an endorsement or recommendation of the treatment sites listed and is not a comprehensive list of all treatment sites that handle TEZSPIRE in your area. Note that there may be other treatment sites that handle TEZSPIRE and participate in a particular patient's pharmacy or medical benefit plan. The list of Treatment Sites is subject to change. It represents no statement, promise, or guarantee by Amgen Inc. or AstraZeneca Inc. concerning coverage and/or availability of the product for any particular patient and it is the responsibility of the healthcare provider to determine the appropriate services provided to their patients.
*Based on Q2’23-Q3’23 vs Q4’22-Q1’23 NBRx growth rate in major global markets.
SEE MORE
Please see Full Prescribing Information including Patient Information and Instructions for Use.
You may report side effects related to AstraZeneca products by clicking here.